Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$811.23
-1.3%
$759.30
$510.05
$934.62
$50.48B0.46359,331 shs219,875 shs
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$167.15
-2.4%
$169.36
$118.51
$179.64
$7.84B0.731.69 million shs1.42 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.39
-3.1%
$39.61
$35.12
$81.44
$198.27B0.7721.70 million shs11.26 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.30
-1.8%
$27.01
$22.45
$28.75
$144.13B0.3542.29 million shs23.18 million shs
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
$130.80
-3.0%
$129.30
$77.33
$139.19
$8.35B0.859.33 million shs6.61 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+2.42%+4.42%-0.75%+0.02%+54.46%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
-0.76%+0.72%-2.57%-0.72%+46.54%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
Pfizer Inc. stock logo
PFE
Pfizer
-0.83%-2.78%-5.12%-6.65%+16.95%
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
-0.74%+0.89%-0.64%+9.76%+76.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$811.23
-1.3%
$759.30
$510.05
$934.62
$50.48B0.46359,331 shs219,875 shs
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$167.15
-2.4%
$169.36
$118.51
$179.64
$7.84B0.731.69 million shs1.42 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.39
-3.1%
$39.61
$35.12
$81.44
$198.27B0.7721.70 million shs11.26 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.30
-1.8%
$27.01
$22.45
$28.75
$144.13B0.3542.29 million shs23.18 million shs
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
$130.80
-3.0%
$129.30
$77.33
$139.19
$8.35B0.859.33 million shs6.61 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+2.42%+4.42%-0.75%+0.02%+54.46%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
-0.76%+0.72%-2.57%-0.72%+46.54%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
Pfizer Inc. stock logo
PFE
Pfizer
-0.83%-2.78%-5.12%-6.65%+16.95%
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
-0.74%+0.89%-0.64%+9.76%+76.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.92
Moderate Buy$1,017.7825.83% Upside
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.74
Moderate Buy$167.19-0.07% Downside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5647.98% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.8413.93% Upside
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
2.73
Moderate Buy$130.75-0.07% Downside

Current Analyst Ratings Breakdown

Latest XBI, IBB, PFE, NVO, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/8/2026
argenex SE stock logo
ARGX
argenex
Boost Price TargetBuy$1,120.00 ➝ $1,135.00
5/8/2026
argenex SE stock logo
ARGX
argenex
Boost Price TargetOverweight$1,247.00 ➝ $1,260.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/22/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHold (C-)Sell (D+)
4/20/2026
argenex SE stock logo
ARGX
argenex
Reiterated RatingHold (C)
4/20/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$25.00
4/16/2026
Pfizer Inc. stock logo
PFE
Pfizer
Initiated CoverageOutperform$33.00
4/13/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$25.00 ➝ $27.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B11.84$21.50 per share37.63$118.34 per share6.84
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.23$4.41 per share10.04$7.12 per share6.22
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.31$4.29 per share5.90$15.86 per share1.60
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$22.4636.0124.861.2831.31%33.28%28.16%7/23/2026 (Estimated)
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.4012.884.1937.23%63.31%22.19%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.338.85N/A11.83%19.44%8.41%N/A
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/A11.47N/AN/AN/AN/AN/AN/A

Latest XBI, IBB, PFE, NVO, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
argenex SE stock logo
ARGX
argenex
$5.74$5.52-$0.22$5.52$1.44 billion$1.31 billion
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
3/31/2026Q1 2026
argenex SE stock logo
ARGX
argenex
N/A$5.52N/A$5.52N/A$1.31 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
2/26/2026Q4 2025
argenex SE stock logo
ARGX
argenex
$6.05$8.02+$1.97$8.02$1.30 billion$1.32 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.390.23%N/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.82%+21.74%41.08%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.68%-13.20%131.30%16 Years
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
$0.440.33%N/AN/AN/A

Latest XBI, IBB, PFE, NVO, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
3/16/2026
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
Quarterly$0.12180.29%3/17/20263/17/20263/20/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.23
4.87
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/A

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.19 million60.68 millionOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A46.90 millionN/AOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/A63.80 millionN/ANot Optionable

Recent News About These Companies

Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
2 Ways to Play the Big Pharma Patent Cliff
...
Biotech ETF (XBI) Hits New 52-Week High
Biotech stocks are among today's winners

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$811.23 -10.90 (-1.33%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$167.15 -4.18 (-2.44%)
As of 02:40 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.39 -1.41 (-3.07%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$25.30 -0.46 (-1.77%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

SPDR S&P Biotech ETF stock logo

SPDR S&P Biotech ETF NYSEARCA:XBI

$130.80 -4.05 (-3.00%)
As of 02:41 PM Eastern

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.